Coronary disease & ACS

Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study

Eur Heart J Cardiovasc PharmacotherPublished nationwide cohort study

Authors' conclusion

Discontinuation of secondary preventive medications was common, but so was reinitiation. Thus, the proportion of patients with ongoing treatment was 91%-92% at 1 year and 74%-79% at 12 years after the MI. This study, which did not assess reasons for drug discontinuation, indicates that long-term utilization of secondary preventive medication after MI may not be as low as previously thought.

Study context

Population
Patients with a first-time myocardial infarction (MI) (2006–2021) registered in the nationwide Swedish MI register SWEDEHEART, surviving >30 days, and discharged with a new prescription of the drug (statins, beta-blockers, aspirin, renin-angiotensin-aldosterone system (RAAS) inhibitors; separate analyses for each drug)patients included in the analyses · discharged with a statin 122,288 · discharged with a RAAS inhibitor 79,968 · discharged with a beta-blocker 105,095 · discharged with aspirin 127,463
Participants
159,155 patients
Exposure
Statin vs RAAS inhibitor vs beta-blocker vs aspirin
  • Statinn = 122,288
  • RAAS inhibitorn = 79,968
  • Beta-blockern = 105,095
  • Aspirinn = 127,463
Outcome
Filled first prescription for the drug

Main finding

As reported in the abstract

Proportion of patients who filled their first prescription

95%-97%

Observational data: associations, not effects.

Further findings

Treatment discontinuation (≥90-day period of non-treatment after the end of previous prescriptions), range across drugs · 1, 5 and 12 years

1 year
12% to 14%
5 years
27%-37%
12 years
36%-51%

Reinitiation among those who discontinued treatment, range across drugs · 1, 5 and 12 years after discontinuation

1 year
28%-46%
5 years
42%-62%
12 years
47%-67%
  • Among those who discontinued treatment

Alive with ongoing treatment (regardless of previous discontinuation/reinitiation episodes) · 1, 5 and 12 years after the index MI

1 year
91%-92%
5 years
79%-82%
12 years
74%-79%

Original publication

Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. Published 4 November 2025. doi:10.1093/ehjcvp/pvaf079

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.